BMT CTN 2203
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
What's the purpose of the trial?
Accepting patients
For Healthcare Professionals Only
This site is intended for healthcare professionals in the US. Patients and care partners can explore and connect with MDS clinical trials through our patient portal.
Participating Centers
There are 20 centers participating in this trial. Enter a location below to find the closest center.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- Cyclophosphamide is a chemotherapy agent used in the treatment of cancer.
- Methotrexate is a chemotherapy medication that may be used in the treatment of many different cancers.
- Mycophenolate Mofetil is an immunosuppressive medication used to help prevent rejection in patients who have had a transplant.
- Ruxolitinib is a tyrosine kinase inhibitor in development for the treatment of several different blood cancers.
- Tacrolimus is an immunosuppressive medication used to help prevent rejection in patients who have had a transplant.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Accepting patients
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.